Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects
- Conditions
- DermatitisDermatitis, AtopicEczemaSkin DiseasesSkin Diseases, GeneticGenetic Diseases, InbornSkin Diseases, EczematousHypersensitivityHypersensitivity, ImmediateImmune System Diseases
- Interventions
- Registration Number
- NCT03627767
- Lead Sponsor
- Pfizer
- Brief Summary
B7451014 is a Phase 3 study to investigate PF-04965842 in patients aged 12 years and over with a minimum body weight of 40 kg who have moderate to severe atopic dermatitis. Subjects responding well to an initial open-label 12 week treatment of PF-04965842 (200 mg) taken orally once daily (QD) will be identified and randomized in a double-blind manner to receive 200 mg QD PF-04965842, 100 mg QD PF-04965842, or QD placebo. Efficacy and safety of 2 doses of PF-04965842 will be evaluated relative to placebo over 40 weeks. Subjects experiencing significant worsening of their symptoms, i.e., protocol-defined flare, enter 12 weeks rescue treatment and receive 200 mg PF-04965842 together with a marketed topical medicine. Eligible patients will have the option to enter a long-term extension study after completing the initial 12 week treatment, the 12 week rescue treatment, and the 40 week blinded treatment.
- Detailed Description
Responder criteria for randomization at week 12 are defined as a) achieving an IGA of clear (0) or almost clear (1) (on a 5 point scale), b) a reduction from IGA baseline of 2 or more points, and c) reaching an EASI-75 response compared to baseline. Flare requiring rescue treatment is defined as a loss of at least 50% of the EASI response at Week 12 and an IGA score of 2 or higher.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1235
- 12 years of age or older with a minimum body weight of 40 kg
- Diagnosis of atopic dermatitis (AD) for at least 1 year and current status of moderate to severe disease (>= the following scores: BSA10%, IGA 3, EASI 16, Pruritus NRS 4)
- Recent history of inadequate response or inability to tolerate topical AD treatments or require systemic treatments for AD control
- Unwilling to discontinue current AD medications prior to the study or require treatment with prohibited medications during the study
- Prior treatment with JAK inhibitors
- Other active nonAD inflammatory skin diseases or conditions affecting skin
- Medical history including thrombocytopenia, coagulopathy or platelet dysfunction, Q wave interval abnormalities, current or history of certain infections, cancer, lymphoproliferative disorders and other medical conditions at the discretion of the investigator
- Pregnant or breastfeeding women, or women of childbearing potential who are unwilling to use contraception
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo QD Placebo Double-blind randomized treatment following open label run-in period. PF-04965842 200 mg QD PF-04965842 200 mg Double-blind randomized treatment following open label run-in period. PF-04965842 100 mg QD PF-04965842 100 mg Double-blind randomized treatment following open label run-in period.
- Primary Outcome Measures
Name Time Method Percentage of Participants With Loss of Response: Double-blind (DB) Period From Day 1 of up to Week 40 of double blind period Percentage of participants with loss of response requiring rescue treatment during double blind period was determined. Loss of response denoted as flare and was define as a loss of at least 50% of EASI total score at Week 12 and with an IGA score of 2 or higher. EASI quantifies severity of participant's atopic dermatitis (AD) based on both severity of lesion clinical signs and % of body surface area (BSA) affected. EASI is a composite scoring by AD clinical evaluator of degree of erythema, induration/papulation, excoriation, and lichenification for each of 4 body regions. EASI total score range from 0.0 to 72.0, with higher scores representing greater severity of AD. IGA assesses severity of AD on 5-point scale (0 to 4, higher scores = more severity), reflecting global consideration of erythema, induration and scaling. Where, 0 = clear; 1 = almost clear; 2 = mild; 3 = moderate and 4 = severe.
Time to Loss of Response: Double-blind Period From date of first dose of randomized treatment until the last dose of randomized treatment (if not entered rescue) or first day of rescue treatment (if entered rescue) (maximum up to Week 40, visit window was extended +/- 45 Days due to COVID 19) Time (in days) to loss of response based on achieving IGA \>=2 was measured from date of first dose of randomized treatment until last dose of randomized treatment (if not entered rescue) or first day of rescue treatment (if entered rescue) and based on EASI, loss of at least 50% of EASI response at Week 12 and IGA score of 2 or higher. IGA assesses severity of AD on 5-point scale (0 to 4, higher scores=more severity), reflecting global consideration of erythema, induration and scaling with scores 0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe. EASI quantifies severity of AD based on severity of lesion clinical signs and % of BSA affected. EASI composite score evaluates degree of erythema, induration/papulation, excoriation, and lichenification.
- Secondary Outcome Measures
Name Time Method Time to First Loss of Response Based on Investigator's Global Assessment (IGA) Score of 2 or Higher: Double-blind Period From date of first dose of randomized treatment until the last dose of randomized treatment (if not entered rescue) or first day of rescue treatment (if entered rescue) (maximum up to Week 40, visit window +/- 7 Days) Time (in days) to loss of response based on achieving IGA \>=2 (for the first time) as measured from date of first dose of randomized treatment until the last dose of randomized treatment (if not entered rescue) or first day of rescue treatment (if entered rescue). IGA assesses severity of AD on a 5-point scale (0 to 4, higher scores indicated more severity), reflecting global consideration of erythema, induration and scaling. Where, 0 = clear, AD is cleared; 1 = almost clear, AD not entirely cleared, light pink residual lesions; 2 = mild, AD with light red lesions; 3 = moderate, AD with red lesions; 4 = severe, AD with deep, dark red lesions.
Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of Clear (0) or Almost Clear (1) and a Reduction of Greater Than or Equal to (>=) 2 Points From Baseline at Weeks 12, 16, 28, 40, and 52: Double-blind Period Baseline, Weeks 12, 16, 28, 40 and 52 IGA assessed severity of AD on a 5-point scale (0 to 4, higher scores indicated more severity), reflecting global consideration of erythema, induration and scaling. Where, 0 = clear, AD is cleared; 1 = almost clear, AD not entirely cleared, light pink residual lesions; 2 = mild, AD with light red lesions; 3 = moderate, AD with red lesions; 4 = severe, AD with deep dark red lesions.
Percentage of Participants Achieving Eczema Area and Severity Index (EASI) Response >=50% Improvement From Baseline at Weeks 12, 16, 28, 40 and 52: Double-blind Period Baseline, Weeks 12, 16, 28, 40 and 52 EASI quantifies severity of participant's AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of BSA affected. Severity of clinical signs of AD (erythema \[E\], induration/papulation \[I\], excoriation \[Ex\] and lichenification \[L\]) was scored separately for each of 4 body regions (head and neck \[h\], upper limbs \[u\], trunk \[t\] \[including axillae and groin\] and lower limbs \[l\] \[including buttocks\]) on 4-point scale: 0 = absent; 1 = mild; 2 = moderate; 3 = severe. EASI area score was based upon % BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score = 0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); where A = area score. Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD.
Percentage of Participants Achieving Eczema Area and Severity Index (EASI) Response >=75% Improvement From Baseline at Weeks 12, 16, 28, 40 and 52: Double-blind Period Baseline, Weeks 12, 16, 28, 40 and 52 EASI quantifies severity of participant's AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of BSA affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\] and lower limbs \[including buttocks\]) on 4-point scale: 0 = absent; 1 = mild; 2 = moderate; 3 = severe. EASI area score was based upon % BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score = 0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll). Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD.
Percentage of Participants Achieving Eczema Area and Severity Index (EASI) Response >=90% Improvement From Baseline at Weeks 12, 16, 28, 40 and 52: Double-blind Period Baseline, Weeks 12, 16, 28, 40 and 52 EASI quantifies severity of participant's AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of BSA affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\] and lower limbs \[including buttocks\]) on 4-point scale: 0 = absent; 1 = mild; 2 = moderate; 3 = severe. EASI area score was based upon % BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score = 0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll). Total EASI score ranged from 0.0 to 72.0, higher scores=greater severity of AD.
Percentage of Participants Achieving Eczema Area and Severity Index (EASI) Response >=100% Improvement From Baseline at Weeks 12, 16, 28, 40 and 52: Double-blind Period Baseline, Weeks 12, 16, 28, 40 and 52 EASI quantifies severity of participant's AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of BSA affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\] and lower limbs \[including buttocks\]) on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll). Total EASI score ranged from 0.0 to 72.0, higher scores=greater severity of AD.
Percentage of Participants With Greater Than or Equal 4 Points Improvement in the Numerical Rating Scale (NRS) for Severity of Pruritus From Baseline at Weeks 12, 16, 28, 40 and 52: Double-blind Period Baseline, Weeks 12, 16, 28, 40 and 52 Participants were asked to assess their worst itching due to AD over the past 24 hours on an NRS scale ranged from 0 (no itch) to 10 (worst itch imaginable), where higher scores indicated worse disease status.
Percent Change From Baseline in Body Surface Area (BSA) at Weeks 12, 16, 28, 40 and 52: Double-blind Period Baseline, Weeks 12, 16, 28, 40 and 52 4 body regions evaluated: head and neck, upper limbs, trunk (including axillae, groin/genitals), lower limbs (including buttocks) excluding scalp, palms, soles. BSA calculated by handprint method. Number (No) of handprints (size of participant's hand with fingers in closed position) fitting in affected area of a body region was estimated. Maximum No of handprints were 10, 20, 30, 40 for head and neck, upper limbs, trunk, and lower limbs respectively. Surface area (SA) of body region equivalent to 1 handprint: 1 handprint=10% for head and neck, 5% for upper limbs, 3.33% for trunk and 2.5% for lower limbs. %Change BSA for a body region was calculated as=total No of handprints in a body region\* %SA equivalent to 1 handprint. %BSA for an individual: arithmetic mean of %BSA of all 4 body regions, ranged from 0-100%, higher values=greater AD severity.
Percent Change From Baseline in Scoring Atopic Dermatitis (SCORAD) Total Score at Weeks 12, 16, 28, 40 and 52: Double-blind Period Baseline, Weeks 12, 16, 28, 40 and 52 SCORAD: scoring index for AD combining extent (A), severity (B), subjective symptoms (C). A: rule of 9 used to calculate BSA affected by AD as % of whole BSA for each body region- head and neck 9%; upper limbs 9% each; lower limbs 18% each; anterior trunk 18%; back 18%; genitals 1%. Score of each body region added to determine A (0-100). B: severity of each sign (erythema; edema; oozing; excoriation; skin thickening; dryness) was assessed as none (0), mild (1), moderate (2), severe (3); severity scores added to give B (0-18). C: pruritus and sleep loss, each of these 2 were scored by participant/caregiver using VAS where, 0=no itch/no sleep loss and 10=worst imaginable itch/sleep loss, higher scores=worse symptoms. Scores for itch and sleep loss added to give 'C' (0-20). SCORAD calculated as: A/5+7\*B/2+C; range (0-103); higher values=worse outcome.
Change From Baseline in Scoring Atopic Dermatitis (SCORAD) Visual Analogue Scale (VAS) of Itch and Sleep Loss at Weeks 12, 16, 28, 40 and 52: Double-blind Period Baseline, Weeks 12, 16, 28, 40 and 52 SCORAD: scoring index for AD combining extent (A), severity (B), subjective symptoms (C). A: rule of 9 used to calculate BSA affected by AD as % of whole BSA for each body region-head and neck 9%; upper limbs 9% each; lower limbs 18% each; anterior trunk 18%; back 18%; genitals 1%. Score of each body region added to determine A (0-100). B: severity of each sign (erythema; edema; oozing; excoriation; skin thickening; dryness) was assessed as none (0), mild (1), moderate (2), severe (3). Severity scores added to give B (0-18). C: pruritus and sleep loss, each were scored by participant/caregiver using VAS where, 0=no itch/no sleep loss and 10=worst imaginable itch/sleep loss, higher scores=worse symptoms. Scores for itch and sleep loss added to give 'C' (0-20). SCORAD calculated as: A/5+7\*B/2+C; range (0-103); higher values=worse outcome.
Percentage of Participants With >=50% Improvement From Baseline in Scoring Atopic Dermatitis (SCORAD) Response at Weeks 12, 16, 28, 40 and 52: Double-blind Period Baseline, Weeks 12, 16, 28, 40 and 52 SCORAD: scoring index for AD combining extent (A), severity (B), subjective symptoms (C). A: rule of 9 used to calculate BSA affected by AD as % of whole BSA for each body region- head and neck 9%; upper limbs 9% each; lower limbs 18% each; anterior trunk 18%; back 18%; genitals 1%. Score of each body region added to determine A (0-100). B: severity of each sign (erythema; edema; oozing; excoriation; skin thickening; dryness) was assessed as none (0), mild (1), moderate (2), severe (3). Severity scores added to give B (0-18). C: pruritus and sleep loss, each were scored by participant/caregiver using VAS where, 0=no itch/no sleep loss and 10=worst imaginable itch/sleep loss, higher scores=worse symptoms. Scores for itch and sleep loss added to give 'C' (0-20). SCORAD calculated as: A/5+7\*B/2+C; range (0-103); higher values=worse outcome.
Percentage of Participants With >=75% Improvement From Baseline in Scoring Atopic Dermatitis (SCORAD) Response at Weeks 12, 16, 28, 40 and 52: Double-blind Period Baseline, Weeks 12, 16, 28, 40 and 52 SCORAD: scoring index for AD combining extent (A), severity (B), subjective symptoms (C). A: rule of 9 used to calculate BSA affected by AD as % of whole BSA for each body region- head and neck 9%; upper limbs 9% each; lower limbs 18% each; anterior trunk 18%; back 18%; genitals 1%. Score of each body region added to determine A (0-100). B: severity of each sign (erythema; edema; oozing; excoriation; skin thickening; dryness) was assessed as none (0), mild (1), moderate (2), severe (3). Severity scores added to give B (0-18). C: pruritus and sleep loss, each were scored by participant/caregiver using VAS where, 0=no itch/no sleep loss and 10=worst imaginable itch/sleep loss, higher scores=worse symptoms. Scores for itch and sleep loss added to give 'C' (0-20). SCORAD calculated as: A/5+7\*B/2+C; range (0-103); higher values=worse outcome.
Percentage of Participants Achieving IGA Response of Clear (0) or Almost Clear (1) and Greater Than or Equal to (>=) 2 Points Improvement From Rescue Baseline at Rescue Weeks 2, 4, 8 and 12: Rescue Period Rescue Baseline: last observation collected between last dose of blinded treatment and Day 1 (first dose day) of rescue treatment, Rescue Weeks 2, 4, 8 and 12 IGA assessed severity of AD on a 5-point scale (0-4, higher scores indicated more severity), reflecting global consideration of erythema, induration and scaling. Where, 0=clear, AD is cleared; 1 = almost clear, AD not entirely cleared, light pink residual lesions; 2 = mild, AD with light red lesions; 3 = moderate, AD with red lesions; 4 = severe, AD with deep, dark red lesions.
Percent Change From Rescue Baseline in Total Eczema Area and Severity Index (EASI) Score at Rescue Weeks 2, 4, 8 and 12: Rescue Period Rescue Baseline: last observation collected between last dose of blinded treatment and Day 1 (first dose day) of rescue treatment, Rescue Weeks 2, 4, 8 and 12 EASI quantifies severity of participant's AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of BSA affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\] and lower limbs \[including buttocks\]) on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll). Total EASI score ranged from 0.0 to 72.0, higher scores=greater severity of AD.
Percentage of Participants Achieving Greater Than or Equal to 4 Points Improvement From Rescue Baseline in Peak Pruritus Numeric Rating Scale (PP-NRS) at Rescue Weeks 2, 4, 8 and 12: Rescue Period Rescue Baseline: last observation collected between last dose of blinded treatment and Day 1 (first dose day) of rescue treatment, Rescue Weeks 2, 4, 8 and 12 Participants were asked to assess their worst itching due to AD over the past 24 hours on an NRS scale ranged from 0 (no itch) to 10 (worst itch imaginable), where higher scores indicated greater severity.
Percent Change From Rescue Baseline in Percent Body Surface Area (BSA) at Rescue Weeks 2, 4, 8 and 12: Rescue Period Rescue Baseline: last observation collected between last dose of blinded treatment and Day 1 (first dose day) of rescue treatment, Rescue Weeks 2, 4, 8 and 12 4 body regions were evaluated: head and neck, upper limbs, trunk (including axillae and groin/genitals) and lower limbs (including buttocks). Scalp, palms and soles were excluded. BSA was calculated using handprint method. Number of handprints (size of participant's hand with fingers in a closed position) fitting in affected area of a body region was estimated. Maximum number of handprints were 10 for head and neck, 20 for upper limbs, 30 for trunk and 40 for lower limbs. Surface area of body region equivalent to 1 handprint: 1 handprint was equal to 10% for head and neck, 5% for upper limbs, 3.33% for trunk and 2.5% for lower limbs. Overall % BSA for an individual % BSA of all 4 body regions, ranged from 0 to 100%, with higher values representing greater severity of AD.
Percent Change From Rescue Baseline in Scoring Atopic Dermatitis (SCORAD) Visual Analog Scale (VAS) Score of Itch and Sleep Loss at Rescue Weeks 2, 4, 8 and 12: Rescue Period Rescue Baseline: last observation collected between last dose of blinded treatment and Day 1 (first dose day) of rescue treatment, Rescue Weeks 2, 4, 8 and 12 SCORAD: scoring index for AD combining extent (A), severity (B), subjective symptoms (C). A: rule of 9 used to calculate BSA affected by AD as % of whole BSA for each body region- head and neck 9%; upper limbs 9% each; lower limbs 18% each; anterior trunk 18%; back 18%; genitals 1%. Score of each body region added to determine A (0-100). B: severity of each sign (erythema; edema; oozing; excoriation; skin thickening; dryness) was assessed as none (0), mild (1), moderate (2), severe (3). Severity scores added to give B (0-18). C: pruritus and sleep loss, each were scored by participant/caregiver using VAS where, 0=no itch/no sleep loss and 10=worst imaginable itch/sleep loss, higher scores=worse symptoms. Scores for itch and sleep loss added to give 'C' (0-20). SCORAD calculated as: A/5+7\*B/2+C; range (0-103); higher values=worse outcome.
Percentage of Participants With 50% Improvement in Scoring Atopic Dermatitis (SCORAD) From Rescue Baseline at Rescue Weeks 2, 4, 8 and 12: Rescue Period Rescue Baseline: last observation collected between last dose of blinded treatment and Day 1 (first dose day) of rescue treatment, Rescue Weeks 2, 4, 8 and 12 SCORAD: scoring index for AD combining extent (A), severity (B), subjective symptoms (C). A: rule of 9 used to calculate BSA affected by AD as % of whole BSA for each body region- head and neck 9%; upper limbs 9% each; lower limbs 18% each; anterior trunk 18%; back 18%; genitals 1%. Score of each body region added to determine A (0-100). B: severity of each sign (erythema; edema; oozing; excoriation; skin thickening; dryness) was assessed as none (0), mild (1), moderate (2), severe (3). Severity scores added to give B (0-18). C: pruritus and sleep loss, each were scored by participant/caregiver using VAS where, 0=no itch/no sleep loss and 10=worst imaginable itch/sleep loss, higher scores=worse symptoms. Scores for itch and sleep loss added to give 'C' (0-20). SCORAD calculated as: A/5+7\*B/2+C; range (0-103); higher values=worse outcome.
Percentage of Participants With 75% Improvement in Scoring Atopic Dermatitis (SCORAD) From Rescue Baseline at Rescue Weeks 2, 4, 8 and 12: Rescue Period Rescue Baseline: last observation collected between last dose of blinded treatment and Day 1 (first dose day) of rescue treatment, Rescue Weeks 2, 4, 8 and 12 SCORAD: scoring index for AD combining extent (A), severity (B), subjective symptoms (C). A: rule of 9 used to calculate BSA affected by AD as % of whole BSA for each body region- head and neck 9%; upper limbs 9% each; lower limbs 18% each; anterior trunk 18%; back 18%; genitals 1%. Score of each body region added to determine A (0-100). B: severity of each sign (erythema; edema; oozing; excoriation; skin thickening; dryness) was assessed as none (0), mild (1), moderate (2), severe (3). Severity scores added to give B (0-18). C: pruritus and sleep loss, each were scored by participant/caregiver using VAS where, 0=no itch/no sleep loss and 10=worst imaginable itch/sleep loss, higher scores=worse symptoms. Scores for itch and sleep loss added to give 'C' (0-20). SCORAD calculated as: A/5+7\*B/2+C; range (0-103); higher values=worse outcome.
Percentage of Participants Achieving Patient Global Assessment (PtGA) Response of 'Clear (0)' or 'Almost Clear (1)' and Greater Than or Equal to 2 Points Improvement From Baseline at Weeks 12, 16, 28, 40 and 52: Double-blind Period Baseline, Weeks 12, 16, 28, 40 and 52 Participant responded to the following question: "Overall, how would you describe your Atopic Dermatitis right now?" on a 5-point scale: 0= clear; 1= almost clear; 2= mild; 3= moderate; and 4= severe. Higher scores indicated more severity.
Change From Baseline in Dermatology Life Quality Index (DLQI) Score for Adults at Weeks 12, 16, 28, 40 and 52: Double-blind Period Baseline, Weeks 12, 16, 28, 40 and 52 DLQI was a 10-item questionnaire that measures the impact of skin disease. Each question was evaluated on a 4-point scale (range 0 to 3) where, 0 = not at all, 1= a little, 2= a lot, 3= very much, where higher scores indicated more impact on quality of life. Scores from all 10 questions were added up to give DLQI total score range from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of participants.
Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) Score for Adolescents at Weeks 12, 16, 28, 40 and 52: Double-blind Period Baseline, Weeks 12, 16, 28, 40 and 52 CDLQI is a 10-item questionnaire that measures the impact of skin disease on adolescents (aged 12-17 years) quality of life over the last week. Each question was evaluated on a 4-point scale (range 0 to 3) where, 0 = not at all , 1 = only a little, 2 = quite a lot, 3 = very much, where higher scores indicated more impact on quality of life. Scores from all 10 questions were added up to give CDLQI total score range from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of children.
Change From Baseline in Hospital Anxiety and Depression Scale (HADS) - Anxiety Scale at Weeks 12, 16, 28, 40 and 52: Double-blind Period Baseline, Weeks 12, 16, 28, 40 and 52 HADS: participant rated 14-item questionnaire. HADS consisted of 2 subscales: HADS-Anxiety (HADS-A) scale and HADS-Depression (HADS-D) scale, both of these subscales comprised of 7 items each. Each item was rated on a 4-point scale, score range from 0 to 3, where higher scores indicates more anxiety/depression symptoms. HADS-A assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks). HADS-A: sum of all 7 items resulted in score range of 0 (no presence of anxiety) to 21 (severe feeling of anxiety); higher score indicating greater severity of anxiety.
Change From Baseline in Hospital Anxiety and Depression Scale (HADS) - Depression Scale at Weeks 12, 16, 28, 40 and 52: Double-blind Period Baseline, Weeks 12, 16, 28, 40 and 52 HADS: participant rated 14-item questionnaire. HADS consisted of 2 subscales: HADS-A scale and HADS-D scale, both of these subscales comprised of 7 items each. Each item was rated on a 4-point scale, score range from 0 to 3, where higher scores indicates more anxiety/depression symptoms. HADS-D assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). HADS-D: sum of all 7 items resulted in score range of 0 (no presence of depression) to 21 (severe feeling of depression); higher score indicating greater severity of depression symptoms.
Change From Baseline in Patient Oriented Eczema Measure (POEM) Score at Weeks 12, 16, 28, 40 and 52: Double-blind Period Baseline, Weeks 12, 16, 28, 40 and 52 POEM was a 7-item participant reported outcome (PRO) measure used to assess the impact of AD (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) over the past week. Each item scored as following: no days = 0, 1-2 days = 1, 3-4 days = 2, 5-6 days = 3 and, every day = 4. The total POEM score ranges from 0 to 28, where higher score indicated greater severity.
Change From Baseline in Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) Score at Weeks 12, 16, 28, 40 and 52: Double-blind Period Baseline, Weeks 12, 16, 28, 40 and 52 PSAAD is a daily participant reported symptom electronic diary. Participants rated their symptoms of AD over the past 24 hours, using 11 items (itchy skin, painful skin, dry skin, flaky skin, cracked skin, bumpy skin, red skin, discolored skin \[darker or lighter\], bleeding from skin, seeping or oozing fluid from skin \[other than blood\], and skin swelling). Participants had to think about all the areas of their body affected by their skin condition and chose the number that best described their experience for each of the 11 items, from 0 (no symptoms) to 10 (extreme symptoms), higher scores signified worse skin condition. Total PSAAD score = arithmetic mean of 11 items, 0 (no symptoms) to 10 (extreme symptoms), where higher score = worse skin condition.
Trial Locations
- Locations (235)
Owensboro Dermatology Associates
🇺🇸Owensboro, Kentucky, United States
MediSearch Clinical Trials
🇺🇸Saint Joseph, Missouri, United States
The University of Texas Health Science Center Houston
🇺🇸Houston, Texas, United States
Dermatology Associates of Seattle
🇺🇸Seattle, Washington, United States
"Center of skin-venereal diseases" EOOD, Sofia
🇧🇬Sofia, Bulgaria
"DCC Fokus-5-Medical Establishment for OutpatientCare"EOOD
🇧🇬Sofia, Bulgaria
Outpatient Clinic Of Ventspils
🇱🇻Ventspils, Latvia
Krakowskie Centrum Medyczne Sp. z o.o.
🇵🇱Krakow, Poland
Arke Estudios Clinicos S.A. de C.V.
🇲🇽Cuauhtemoc, Ciudad DE Mexico, Mexico
Universitair Medisch Centrum (UMC) Utrecht
🇳🇱Utrecht, Netherlands
Centrum Medyczne Angelius Provita
🇵🇱Katowice, Poland
Synexus Polska Sp. z o.o. Oddzial w Warszawie
🇵🇱Warszawa, Poland
Lukasz Matusiak "4Health'
🇵🇱Wroclaw, Poland
Pro Familia Altera Sp. z o.o.
🇵🇱Katowice, Poland
Klinika Ambroziak Sp. z o.o.
🇵🇱Warszawa, Poland
ETG Warszawa
🇵🇱Warszawa, Poland
National Cheng-Kung University Hospital
🇨🇳Tainan, Taiwan
SBI RR "Skin and Venereal Dispensary"
🇷🇺Rostov-on-Don, Russian Federation
SPb SBIH "Dermatovenerologic Dispensary #10 - Clinic of dermatology and venerology"
🇷🇺Saint-Petersburg, Russian Federation
University of California San Diego
🇺🇸San Diego, California, United States
Clinical Centre Nis
🇷🇸Nis, Serbia
Hospital Universitario La Paz
🇪🇸Madrid, Spain
Kaohsiung Medical University Chung-Ho Memorial Hospital
🇨🇳Kaohsiung, Taiwan
Hospital Universitario Infanta Leonor
🇪🇸Madrid, Spain
Consorcio Hospital General Universitario de Valencia
🇪🇸Valencia, Spain
Chang Gung Memorial Hospital Linkou Branch
🇨🇳Taoyuan City, Taiwan
Taipei Medical University-Shuang Ho Hospital
🇨🇳New Taipei City, Taiwan
Hospital Universitario y Politecnico La Fe
🇪🇸Valencia, Spain
Hospital Universitario Virgen de la Macarena
🇪🇸Sevilla, Spain
Hospital del Nino Jesus
🇪🇸Madrid, Spain
National Taiwan University Hospital
🇨🇳Taipei, Taiwan
The Third Affiliated Hospital, Sun Yat-sen University
🇨🇳Guangzhou, Guangdong, China
Tongji Hospital, Tongji Medical College,Huazhong University of Science and Technology
🇨🇳Wuhan, Hubei, China
The Second Affiliated Hospital of Zhejiang University School of Medicine/Dermatology Dept
🇨🇳Hangzhou, Zhejiang, China
The First Affiliated Hospital of Zhejiang University School of Medicine/Dermatology and STD Dept
🇨🇳Hangzhou, Zhejiang, China
Zhejiang Provincial People's Hospital/Dermatology Department
🇨🇳Hangzhou, Zhejiang, China
Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
🇨🇳Hangzhou, Zhejiang, China
Shanghai Changzheng Hospital
🇨🇳Shanghai, China
Kansas City Dermatology, P.A.
🇺🇸Overland Park, Kansas, United States
Lynn Health Science Institute
🇺🇸Oklahoma City, Oklahoma, United States
Newton Clinical Research
🇺🇸Oklahoma City, Oklahoma, United States
University of Alabama at Birmingham, Dermatology at the Whitaker Clinic
🇺🇸Birmingham, Alabama, United States
Clinical Research Center of Alabama, LLC
🇺🇸Birmingham, Alabama, United States
Oregon Medical Research Center
🇺🇸Portland, Oregon, United States
Centre de Recherche Dermatologique du Quebec Metropolitain (CRDQ)
🇨🇦Quebec, Canada
Katholisches Kinderkrankenhaus Wilhemstift
🇩🇪Hamburg, Germany
TFS Trial Form Support GmbH
🇩🇪Hamburg, Germany
KO-MED Centra Kliniczne Lublin II
🇵🇱Lublin, Poland
Total Skin and Beauty Dermatology Center, PC
🇺🇸Birmingham, Alabama, United States
Center for Dermatology Clinical Research, Inc.
🇺🇸Fremont, California, United States
Beach Allergy and Asthma Specialty Group, A Medical Corporation
🇺🇸Long Beach, California, United States
Dermatology Specialists, Inc.
🇺🇸Oceanside, California, United States
Southern California Dermatology, Inc.
🇺🇸Santa Ana, California, United States
San Luis Dermatology and Laser Clinic
🇺🇸San Luis Obispo, California, United States
Skin Care Research, LLC
🇺🇸Boca Raton, Florida, United States
Mosaic Dermatology
🇺🇸Santa Monica, California, United States
Bay Pines VAHCS
🇺🇸Bay Pines, Florida, United States
Skin Research Institute
🇺🇸Coral Gables, Florida, United States
Baumann Cosmetic and Research Institute
🇺🇸Miami, Florida, United States
USF Asthma, Allergy & Immunology Clinical Research Unit
🇺🇸Tampa, Florida, United States
Park Avenue Dermatology
🇺🇸Orange Park, Florida, United States
Emory University
🇺🇸Atlanta, Georgia, United States
NorthShore University HealthSystem Dermatology Clinical Trials Unit
🇺🇸Skokie, Illinois, United States
Midwest Allergy Sinus Asthma, SC
🇺🇸Normal, Illinois, United States
Dawes Fretzin Clinical Research Group, LLC
🇺🇸Indianapolis, Indiana, United States
Ds Research
🇺🇸New Albany, Indiana, United States
The Indiana Clinical Trials Center
🇺🇸Plainfield, Indiana, United States
DXP Imaging
🇺🇸Louisville, Kentucky, United States
Meridian Clinical Research, LLC
🇺🇸Baton Rouge, Louisiana, United States
Skin Sciences PLLC
🇺🇸Louisville, Kentucky, United States
Qualmedica Research, LLC
🇺🇸Owensboro, Kentucky, United States
Tulane University Health Sciences Center
🇺🇸New Orleans, Louisiana, United States
Tufts Medical Center
🇺🇸Boston, Massachusetts, United States
Mayo Clinic
🇺🇸Rochester, Minnesota, United States
Saint Louis University Dermatology
🇺🇸Saint Louis, Missouri, United States
M3 - Wake Research, Inc.
🇺🇸Raleigh, North Carolina, United States
Forest Hills Dermatology Group
🇺🇸Kew Gardens, New York, United States
UR Dermatology at College Town
🇺🇸Rochester, New York, United States
Bexley Dermatology Research
🇺🇸Bexley, Ohio, United States
Juva Skin and Laser Center
🇺🇸New York, New York, United States
Paddington Testing Co, Inc.
🇺🇸Philadelphia, Pennsylvania, United States
Dermatology Treatment & Research Center, PA
🇺🇸Dallas, Texas, United States
Innovate Research, LLC
🇺🇸Fort Worth, Texas, United States
Ventavia Research Group Hurst
🇺🇸Hurst, Texas, United States
Dermatology Specialists of Spokane
🇺🇸Spokane, Washington, United States
Virginia Clinical Research, Inc
🇺🇸Norfolk, Virginia, United States
Framingham Centro Medico
🇦🇷La Plata, Buenos Aires, Argentina
CINME Centro de Investigaciones Metabolicas
🇦🇷C.a.b.a., Argentina
Hospital Universitario Austral
🇦🇷Pilar, Buenos Aires, Argentina
Servicio de Investigacion de Patolog-ias Alergicas del Instituto ABC
🇦🇷Rosario, Santa FE, Argentina
University Hospital Brussels
🇧🇪Brussels, Belgium
Buenos Aires Skin
🇦🇷C.a.b.a., Argentina
Cliniques Universitaires Saint-Luc
🇧🇪Brussels, Belgium
Psoriahue Medicina Interdisciplinaria
🇦🇷C.a.b.a, Argentina
University Hospital Antwerp
🇧🇪Edegem, Belgium
CETI - Centro de Estudos em Terapias Inovadoras LTDA.
🇧🇷Curitiba, PR, Brazil
Instituto de Dermatologia e Estética do Brasil LTDA
🇧🇷Rio de Janeiro, RJ, Brazil
Fundacao do ABC - Faculdade de Medicina do ABC
🇧🇷Santo Andre, SP, Brazil
Pesquisare Saude S/S Ltda
🇧🇷Santo Andre, SP, Brazil
Hospital De Clinicas De Porto Alegre
🇧🇷Porto Alegre, RS, Brazil
Associacao dos Funcionarios Públicos do Estado do Rio Grande do Sul - Hospital Ernesto Dornelles
🇧🇷Porto Alegre, RS, Brazil
IBPClin Pesquisa Clinica
🇧🇷Rio de Janeiro, Brazil
MC Asklepii" OOD
🇧🇬Dupnitsa, Bulgaria
MHAT "Dr. Tota Venkova" AD
🇧🇬Gabrovo, Bulgaria
"Mc Sinexus Sofia" Eood
🇧🇬Sofia, Bulgaria
ACIBADEM City Clinic Diagnostic-Consultative Center EOOD
🇧🇬Sofia, Bulgaria
"ACIBADEM City Clinic Medical Center Varna" EOOD
🇧🇬Varna, Bulgaria
Dermatology Research Institute
🇨🇦Calgary, Alberta, Canada
Stratica Medical
🇨🇦Edmonton, Alberta, Canada
Alberta Dermasurgery Center
🇨🇦Edmonton, Alberta, Canada
Wiseman Dermatology Research Inc.
🇨🇦Winnipeg, Manitoba, Canada
Karma Clinical Trials, Inc.
🇨🇦St. John's, Newfoundland and Labrador, Canada
CCA Medical Research
🇨🇦Ajax, Ontario, Canada
SimcoDerm Medical and Surgical Dermatology Center
🇨🇦Barrie, Ontario, Canada
Lynderm Research Inc.
🇨🇦Markham, Ontario, Canada
DermEdge Research
🇨🇦Mississauga, Ontario, Canada
Peking University First Hospital
🇨🇳Beijing, China
Universitaetsklinikum Bonn
🇩🇪Bonn, Germany
Dermatology Ottawa Research Centre
🇨🇦Ottawa, Ontario, Canada
K. Papp Clinical Research
🇨🇦Waterloo, Ontario, Canada
SKiN Centre for Dermatology
🇨🇦Peterborough, Ontario, Canada
AvantDerm
🇨🇦Toronto, Ontario, Canada
Office of Dr. Paul Adam
🇨🇦Scarborough, Ontario, Canada
Centro Medico SkinMed Limitada
🇨🇱Santiago, Region Metropolitana, Chile
Clinica Dermacross S.A.
🇨🇱Santiago, Region Metropolitana, Chile
XLR8 Medical Research Inc.
🇨🇦Windsor, Ontario, Canada
Beijing Friendship Hospital, Capital Medical University
🇨🇳Beijing, Beijing, China
Centro Internacional de Estudios Clinicos - CIEC
🇨🇱Santiago, Region Metropolitana, Chile
Hospital Clinico Universidad de Chile
🇨🇱Santiago, Región Metropolitana, Chile
The First Affiliated Hospital, Sun Yat-sen University
🇨🇳Guangzhou, Guangdong, China
The Second Affiliated Hospital of Army Medical University, PLA
🇨🇳Chongqing, Chongqing, China
The University of Hong Kong - Shenzhen Hospital
🇨🇳Shenzhen, Guangdong, China
The Third Xiangya Hospital of Central South University
🇨🇳Changsha, Hunan, China
The Second Xiangya Hospital of Central South University
🇨🇳Changsha, Hunan, China
Dermatology Hospital of Jiangxi Province
🇨🇳Nanchang, Jiangxi, China
The First Affiliated Hospital With Nanjing University
🇨🇳Nanjing, Jiangsu, China
Jinan Central Hospital
🇨🇳Jinan, Shandong, China
Huashan Hospital Fudan University
🇨🇳Shanghai, Shanghai, China
Tianjin Medical University General Hospital, Dermatological Department
🇨🇳Tianjin, Tianjin, China
Shanghai Dermatology Hospital
🇨🇳Shanghai, China
Charite - Universitaetsmedizin Berlin, Klinik fuer Dermatologie, Venerologie und Allergologie
🇩🇪Berlin, Germany
Rothhaar Studien GmbH
🇩🇪Berlin, Germany
Klinikum Bielefeld Rosenhoehe
🇩🇪Bielefeld, Germany
Hautzentrum Friedrichshain Studien
🇩🇪Berlin, Germany
Universitaetsklinikum Essen
🇩🇪Essen, Germany
Universitaetsklinikum Carl Gustav Carus der Technischen Universitaet Dresden
🇩🇪Dresden, Germany
Universitaetsklinikum Erlangen
🇩🇪Erlangen, Germany
Universitätsklinikum und Poliklinik für Dermatologie und Venerologie
🇩🇪Halle, Germany
SRH Wald-Klinikum Gera GmbH
🇩🇪Gera, Germany
Klinische Forschung Hamburg GmbH
🇩🇪Hamburg, Germany
MENSINGDERMA research GmbH
🇩🇪Hamburg, Germany
Medizinische Hochschule Hannover
🇩🇪Hannover, Germany
Praxis Dr. med. Beate Schwarz
🇩🇪Langenau, Germany
Soroka University Medical Center
🇮🇱Beer Sheva, Israel
Hautaerztliche Gemeinschaftspraxis Dres. Leitz und Kollegen
🇩🇪Stuttgart, Germany
Universitaetsklinikum Schleswig-Holstein
🇩🇪Luebeck, Germany
The Chaim Sheba Medical Center
🇮🇱Ramat-Gan, Israel
Rambam Health Care Campus
🇮🇱Haifa, Israel
Rabin Medical Center
🇮🇱Petah Tikva, Israel
Tel-Aviv Sourasky Medical Center
🇮🇱Tel-Aviv, Israel
AOU Policlinico Sant'Orsola Malpighi
🇮🇹Bologna, BO, Italy
Universita' degli Studi G. D'Annunzio -CeSi-MeT
🇮🇹Chieti, CH, Italy
Ospedale Cristo Re
🇮🇹Roma, Rome, Italy
IFO Istituto Dermatologico San Gallicano IRCCS,
🇮🇹Roma, RM, Italy
Ospedale Luigi Sacco
🇮🇹Milano, Italy
Prof. Giovanni Pellacani AOU Policlinico di Modena Struttura Complessa di Dermatologia
🇮🇹Modena, Italy
Azienda Ospedaliero Universitaria San Martino di Genova
🇮🇹Genova, Italy
Universita del Sacro Cuore, Policlinico Agostino Gemelli, Istituto Di Dermatologia
🇮🇹Rome, Italy
Riga 1st Hospital, Clinic of Dermatology and STD
🇱🇻Riga, Latvia
Health and Aesthetics Ltd
🇱🇻Riga, Latvia
Health Centre 4 Ltd, Dermatology Clinics
🇱🇻Riga, Latvia
Phylasis Clinicas Research S. de R.L. de C.V.
🇲🇽Cuautitlan Izcalli, Estado DE Mexico, Mexico
Centro de Dermatologia de Monterrey
🇲🇽Monterrey, Nuevo LEON, Mexico
JM Research SC
🇲🇽Cuernavaca, Morelos, Mexico
Derma Norte del Bajio S.C
🇲🇽Aguascalientes, Mexico
Centro de Investigacion Integral Medivest S.C.
🇲🇽Chihuahua, Mexico
Nasz Lekarz Osrodek Badan Klinicznych
🇵🇱Bydgoszcz, Poland
Centrum Medyczne SENSEMED
🇵🇱Chorzow, Poland
Uniwersyteckie Centrum Kliniczne, Klinika Dermatologii, Wenerologii i Alergologii
🇵🇱Gdansk, Poland
Copernicus Podmiot Leczniczy Sp. z.o.o., Oddzial Dermatologii
🇵🇱Gdansk, Poland
Silmedic Sp. z o.o., Oddzial w Katowicach
🇵🇱Katowice, Poland
Malopolskie Centrum Kliniczne
🇵🇱Krakow, Poland
Centrum Badan Klinicznych JCI
🇵🇱Krakow, Poland
NZOZ "DERMED" Centrum Medyczne Sp. z o.o. - Oddzial w Lodzi
🇵🇱Lodz, Poland
O?rodek Bada? Klinicznych Appletreeclinics
🇵🇱Lodz, Poland
Centrum Terapii Wspolczesnej J.M. Jasnorzewska Spolka Komandytowo-Akcyjna
🇵🇱Lodz, Poland
MTZ Clinical Research Sp. z o.o.
🇵🇱Warszawa, Poland
Dermoklinika-Centrum Medyczne s.c.
🇵🇱Lodz, Poland
Dermedic Jacek Zdybski
🇵🇱Ostrowiec Swietokrzyski, Poland
Laser Clinic S.C. dr Tomasz Kochanowski dr Andrzej Krolicki
🇵🇱Szczecin, Poland
Alergo-Med Specjalistyczna Przychodnia Lekarska Sp. z o.o.
🇵🇱Tarnow, Poland
Centralny Szpital Kliniczny Ministerstwa Spraw Wewnetrznych i Administracji w Warszawie
🇵🇱Warszawa, Poland
RCMed Oddzial Warszawa
🇵🇱Warszawa, Poland
Wojskowy Instytut Medyczny, Klinika Dermatologiczna
🇵🇱Warszawa, Poland
Synexus Polska Sp. z o.o. Oddzial we Wroclawiu
🇵🇱Wroclaw, Poland
SC Centrul Medical de Diagnostic si Tratament Ambulator Neomed SRL
🇷🇴Brasov, JUD. Brasov, Romania
SBIH "Chelyabinsk Regional Clinical Dermatovenerology dispensary"
🇷🇺Chelyabinsk, Russian Federation
Kliniczny Oddzial Chorob Wewnetrznych, Dermatologii i Alergologii
🇵🇱Zabrze, Poland
SC Delta Health Care SRL
🇷🇴Bucuresti, Romania
Cabinet Medical de Dermatovenerologie Prof. Dr. Orasan Remus Ioan
🇷🇴Cluj-Napoca, Jud. Cluj, Romania
Clinic of FSBEI HE Kirov SMU MOH Russia
🇷🇺Kirov, Russian Federation
Limited Liability Company "Medical Center "Rheuma-Med"
🇷🇺Kemerovo, Russian Federation
NRC Institute of Immunology FMBA of Russia
🇷🇺Moscow, Russian Federation
SBI RR "Regional Clinical Skin and Veneral Dispensary"
🇷🇺Ryazan, Russian Federation
Medical Research Institute, LLC
🇷🇺Saint Petersburg, Russian Federation
FSBI "State Research Centre of Dermatovenereology and Cosmetology" MoH RF
🇷🇺Moscow, Russian Federation
LLC "Pierre Wolkenstein Clinic of Skin Diseases"
🇷🇺Saint-Petersburg, Russian Federation
Vitiligo center
🇷🇺Saint-Petersburg, Russian Federation
FSBEI HE "St. Petersburg State Pediatric Medical University" MoH RF
🇷🇺Saint-Petersburg, Russian Federation
Limited Liability Company "Sanavita"
🇷🇺Saint-Petersburg, Russian Federation
FSBEI HE I.P.Pavlov SPbSMU MOH Russia
🇷🇺Saint-Petersburg, Russian Federation
Military Medical Academy
🇷🇸Belgrade, Serbia
RSBIH "Smolensk Regional Clinical Hospital"
🇷🇺Smolensk, Russian Federation
General Hospital Pancevo
🇷🇸Pancevo, Serbia
Fakultna Nemocnica s Poliklinikou F. D. Roosevelta Banska Bystrica
🇸🇰Banska Bystrica, Slovakia
Narodny ustav detskych chorob, Detska dermatovenerologicka klinika LF UK a NUDCH
🇸🇰Bratislava, Slovakia
BeneDerma s.r.o.
🇸🇰Bratislava, Slovakia
Derma therapy spol. s.r.o, Dermatovenerologicka ambulancia
🇸🇰Bratislava, Slovakia
Nemocnica Kosice-Saca, a.s., 1. sukromna nemocnica, Kozna ambulancia
🇸🇰Kosice-Saca, Slovakia
Derma-beauty, s.r.o., Dermatovenerologicka ambulancia
🇸🇰Nitra, Slovakia
Pedi-Derma s.r.o., Dermatovenerologicka ambulancia
🇸🇰Kosice, Slovakia
SANARE spol. s.r.o., Dermatovenerologicka ambulancia
🇸🇰Svidnik, Slovakia
Hospital Universitari Germans Trias i Pujol
🇪🇸Badalona, Barcelona, Spain
Hospital de la Santa Creu i Sant Pau
🇪🇸Barcelona, Spain
Hospital Sant Joan de Deu
🇪🇸Esplugues de Llobregat, Barcelona, Spain
Hospital Universitario Puerta de Hierro de Majadahonda
🇪🇸Majadahonda, Madrid, Spain
Hospital Clinic de Barcelona
🇪🇸Barcelona, Spain
Hospital General Universitario de Alicante
🇪🇸Alicante, Spain
Dermatologic Surgery Specialists, PC
🇺🇸Macon, Georgia, United States
Hospital Universitario Reina Sofia
🇪🇸Cordoba, Spain
Hospital Universitario de La Princesa
🇪🇸Madrid, Spain
Tien Q Nguyen MD Inc dba First OC Dermatology
🇺🇸Fountain Valley, California, United States
Hospital General Universitario Gregorio Maranon
🇪🇸Madrid, Spain
Chung Shan Medical University Hospital
🇨🇳Taichung City, Taiwan
Health Concepts
🇺🇸Rapid City, South Dakota, United States